Literature DB >> 1898896

A protective human monoclonal antibody directed to the outer core region of Pseudomonas aeruginosa lipopolysaccharide.

M Terashima1, I Uezumi, T Tomio, M Kato, K Irie, T Okuda, S Yokota, H Noguchi.   

Abstract

The protective activity against experimental Pseudomonas aeruginosa infection of a human monoclonal antibody, MH-4H7, which is thought to recognize L-rhamnose and its neighboring residues in the outer core region of P. aeruginosa lipopolysaccharide and which binds to strains of Homma serotypes A, F, G, H, K, and M, was studied in normal, burned, and leukopenic mice. MH-4H7 at doses of 0.1 to 1.0 micrograms per mouse (5 to 50 micrograms/kg) was effective against serotype A, F, G, H, and K clinical isolates of P. aeruginosa tested in normal mice but not against strains of serotype M, B, E, or I. The 50% protective doses were calculated to be 0.01 and 0.1 micrograms per mouse against challenge with serotype G strains and 3 to 8 micrograms per mouse against challenge with serotype A strains. MH-4H7 promoted macrophage-mediated opsonophagocytosis of serotype A, F, G, H, and K strains but not of serotype M strains. The opsonophagocytic activity, expressed as the reduction rate of viable bacteria in the presence of MH-4H7, macrophages, and complement, was higher against serotype G strains (more than 90%) than against serotype A strains (60 to 80%) and serotype F, H, and K strains (50 to 86%). It was correlated with the protective activity but not with the binding intensity of MH-4H7 to the organisms. In addition, burned and leukopenic mice as well as normal mice infected with serotype G strains recovered from a very low dosage of MH-4H7. Thus, a monoclonal antibody directed to the outer core region of P. aeruginosa lipopolysaccharide was effective against infection with a wide range of O-serotype strains of P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1898896      PMCID: PMC257697          DOI: 10.1128/iai.59.1.1-6.1991

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Human monoclonal antibodies to Pseudomonas aeruginosa produced by EBV-transformed cells.

Authors:  H Suzuki; Y Okubo; M Moriyama; M Sasaki; Y Matsumoto; T Hozumi
Journal:  Microbiol Immunol       Date:  1987       Impact factor: 1.955

2.  Pseudomonas pneumonia. A retrospective study of 36 cases.

Authors:  J E Pennington; H Y Reynolds; P P Carbone
Journal:  Am J Med       Date:  1973-08       Impact factor: 4.965

3.  Human immunity to Pseudomonas aeruginosa. II. Relationship between heat-stable opsonins and type-specific lipopolysaccharides.

Authors:  L S Young
Journal:  J Infect Dis       Date:  1972-09       Impact factor: 5.226

4.  Lipopolysaccharide pseudomonas vaccine: efficacy against pulmonary infection with Pseudomonas aeruginosa.

Authors:  J E Pennington
Journal:  J Infect Dis       Date:  1979-07       Impact factor: 5.226

5.  Protective activity of an intravenous immune globulin (human) enriched in antibody against lipopolysaccharide antigens of Pseudomonas aeruginosa.

Authors:  M S Collins; R E Roby
Journal:  Am J Med       Date:  1984-03-30       Impact factor: 4.965

6.  Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: description of a burned mouse model.

Authors:  D D Stieritz; I A Holder
Journal:  J Infect Dis       Date:  1975-06       Impact factor: 5.226

7.  Characterization of the human immune response to a polysaccharide vaccine from Pseudomonas aeruginosa.

Authors:  G B Pier; D M Thomas
Journal:  J Infect Dis       Date:  1983-08       Impact factor: 5.226

8.  Flagellar preparations from Pseudomonas aeruginosa: animal protection studies.

Authors:  I A Holder; R Wheeler; T C Montie
Journal:  Infect Immun       Date:  1982-01       Impact factor: 3.441

Review 9.  Infections caused by Pseudomonas aeruginosa.

Authors:  G P Bodey; R Bolivar; V Fainstein; L Jadeja
Journal:  Rev Infect Dis       Date:  1983 Mar-Apr

10.  Protection against Pseudomonas aeruginosa infection in a murine burn wound sepsis model by passive transfer of antitoxin A, antielastase, and antilipopolysaccharide.

Authors:  S J Cryz; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1983-03       Impact factor: 3.609

View more
  11 in total

Review 1.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

2.  Effect of antiflagellar human monoclonal antibody on gut-derived Pseudomonas aeruginosa sepsis in mice.

Authors:  T Matsumoto; K Tateda; S Miyazaki; N Furuya; A Ohno; Y Ishii; Y Hirakata; K Yamaguchi
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

3.  Phage display and bacterial expression of a recombinant Fab specific for Pseudomonas aeruginosa serotype O6 lipopolysaccharide.

Authors:  N L Tout; J S Lam
Journal:  Clin Diagn Lab Immunol       Date:  1997-03

4.  Pseudomonas aeruginosa lipopolysaccharide: evidence that the O side chains and common antigens are on the same molecule.

Authors:  K Hatano; J B Goldberg; G B Pier
Journal:  J Bacteriol       Date:  1993-08       Impact factor: 3.490

5.  A bactericidal monoclonal antibody specific for the lipooligosaccharide of Bordetella pertussis reduces colonization of the respiratory tract of mice after aerosol infection with B. pertussis.

Authors:  K T Mountzouros; A Kimura; J L Cowell
Journal:  Infect Immun       Date:  1992-12       Impact factor: 3.441

Review 6.  Pseudomonas aeruginosa lipopolysaccharide: a major virulence factor, initiator of inflammation and target for effective immunity.

Authors:  Gerald B Pier
Journal:  Int J Med Microbiol       Date:  2007-04-27       Impact factor: 3.473

7.  Therapeutic effects of a human antiflagella monoclonal antibody in a neutropenic murine model of Pseudomonas aeruginosa pneumonia.

Authors:  K Oishi; F Sonoda; A Iwagaki; P Ponglertnapagorn; K Watanabe; T Nagatake; A Siadak; M Pollack; K Matsumoto
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

8.  Development, characterization, and biological properties of meningococcal immunotype L3,7,(8),9-specific monoclonal antibodies.

Authors:  A F Verheul; A J Kuipers; A K Braat; H A Dekker; C C Peeters; H Snippe; J T Poolman
Journal:  Clin Diagn Lab Immunol       Date:  1994-11

9.  Mucosal and systemic immunizations with killed Pseudomonas aeruginosa protect against acute respiratory infection in rats.

Authors:  A W Cripps; M L Dunkley; R L Clancy
Journal:  Infect Immun       Date:  1994-04       Impact factor: 3.441

10.  Characterization of lipopolysaccharide-deficient mutants of Pseudomonas aeruginosa derived from serotypes O3, O5, and O6.

Authors:  T Dasgupta; T R de Kievit; H Masoud; E Altman; J C Richards; I Sadovskaya; D P Speert; J S Lam
Journal:  Infect Immun       Date:  1994-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.